OraSure Technologies (NASDAQ:OSUR) Releases Earnings Results, Misses Expectations By $0.04 EPS

OraSure Technologies (NASDAQ:OSUR) released its earnings results on Wednesday. The medical instruments supplier reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), Zacks reports. OraSure Technologies had a negative return on equity of 13.61% and a negative net margin of 47.92%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Submitted two FDA applications in December for a rapid molecular OTC self-test for chlamydia/gonorrhea (Sherlock) and the Colli‑Pee at‑home urine collection device, targeting mid‑year launches and a revenue ramp in H2 2026; management cites a CT/NG TAM of >$1.5 billion.
• International diagnostics trends are stabilizing and OTI is pursuing nearshoring (in‑country assembly in Africa) and integrating BioMedomics to expand distribution of the Sickle SCAN test, with revenue contributions expected beginning in Q1 and through 2026.
• Q4 revenue was $26.8M (core $26.7M) above midpoint guidance and GAAP gross margin improved to 41%; the company ended 2025 with $199M cash, zero debt and $15M of buybacks, but reported a GAAP operating loss of $20.1M and negative operating cash flow, guiding Q1 revenue of $26–29M and expecting operating cash flow breakeven by 2027.
• Operational actions—manufacturing consolidation to Bethlehem, internalizing contract volumes, and an expected decline in R&D as clinical trials wind down—should drive sequential gross margin improvement as capacity utilization increases with revenue growth.

OraSure Technologies Price Performance

NASDAQ OSUR traded down $0.02 during mid-day trading on Wednesday, reaching $2.80. The stock had a trading volume of 539,717 shares, compared to its average volume of 505,879. The stock has a market cap of $200.84 million, a PE ratio of -3.50 and a beta of 0.87. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $4.22. The company has a fifty day moving average price of $2.65 and a 200 day moving average price of $2.79.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. lifted its stake in OraSure Technologies by 12,890.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 49,755 shares of the medical instruments supplier’s stock valued at $120,000 after acquiring an additional 49,372 shares during the period. Russell Investments Group Ltd. grew its stake in shares of OraSure Technologies by 13.3% in the fourth quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier’s stock worth $106,000 after acquiring an additional 5,138 shares during the period. Sei Investments Co. raised its holdings in shares of OraSure Technologies by 16.4% during the third quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock valued at $103,000 after purchasing an additional 4,536 shares during the last quarter. Numerai GP LLC purchased a new position in shares of OraSure Technologies during the fourth quarter valued at approximately $100,000. Finally, Envestnet Asset Management Inc. lifted its position in OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 8,133 shares during the period. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on OSUR. Stephens decreased their target price on shares of OraSure Technologies from $3.50 to $3.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 12th. Weiss Ratings restated a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, OraSure Technologies currently has a consensus rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.